Crisaborole
A nonsteroidal anti-inflammatory ointment used to treat mild to moderate atopic dermatitis (eczema) in adults and children as young as three months. It works by inhibiting phosphodiesterase-4 (PDE4), an enzyme that promotes inflammation in the skin. It provides an alternative to topical corticosteroids without steroid-related side effects.
Peso molecular
251,0500 g/mol
TPSA
62,50 Ų
Áreas terapéuticas
Mecanismo de acción
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Estructura 2D
Cite this structure
Embed this structure
SMILES
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
InChI
InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2
Molecular Formula
C14H10BNO3
HBD / HBA
1 / 4
Enlaces Rotables
2
Átomos Pesados
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A nonsteroidal anti-inflammatory ointment used to treat mild to moderate atopic dermatitis (eczema) in adults and children as young as three months. It works by inhibiting phosphodiesterase-4 (PDE4), an enzyme that promotes inflammation in the skin. It provides an alternative to topical corticosteroids without steroid-related side effects.
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Yes, Crisaborole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL484785. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44591583. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="crisaborole"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/crisaborole/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/crisaborole/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/crisaborole/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="crisaborole"></drugfyi-drug>